{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:54:10Z","timestamp":1780322050550,"version":"3.54.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U2202213"],"award-info":[{"award-number":["U2202213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bioorg.2024.107506","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:05:53Z","timestamp":1717023953000},"page":"107506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors"],"prefix":"10.1016","volume":"149","author":[{"given":"Mengyi","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Ping","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107506_b0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107506_b0010","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0020","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Science : a Publication of the Protein Society"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","article-title":"Jak1 has a dominant role over Jak3 in signal transduction through \u03b3c-containing cytokine receptors","volume":"18","author":"Haan","year":"2011","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0030","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4161\/cbt.20083","article-title":"Novel small molecular inhibitors disrupt the JAK\/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells","volume":"13","author":"Swiatek-Machado","year":"2012","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jep.2013.03.011","article-title":"Inhibitory effects of the root extract of Litsea cubeba (lour.) pers. on adjuvant arthritis in rats","volume":"147","author":"Lin","year":"2013","journal-title":"J. Ethnopharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107506_b0045","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1007\/s00044-018-2215-8","article-title":"Docking study and antiosteoporosis effects of a dibenzylbutane lignan isolated from Litsea cubeba targeting Cathepsin K and MEK1","volume":"27","author":"Peng","year":"2018","journal-title":"Med. Chem. Res."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0050","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/apt.14669","article-title":"Review article: novel oral-targeted therapies in inflammatory bowel disease","volume":"47","author":"White","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0055","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107506_b0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O'Shea","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.immuni.2006.10.007","article-title":"Human tyk2 kinase deficiency: another primary immunodeficiency syndrome","volume":"25","author":"Watford","year":"2006","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0070","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40261-021-01055-0","article-title":"Filgotinib in Rheumatoid Arthritis: A Profile of Its Use","volume":"41","author":"Kim","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107506_b0075","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: First Approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.bioorg.2024.107506_b0080","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10292","key":"10.1016\/j.bioorg.2024.107506_b0090","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jbspin.2015.09.002","article-title":"JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells","volume":"83","author":"Wu","year":"2016","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C7MD00568G","article-title":"Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"9","author":"Chough","year":"2018","journal-title":"Medchemcomm"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0110","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bmc.2018.01.021","article-title":"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"26","author":"Chough","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A Comprehensive Overview of Globally Approved JAK Inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4155\/fmc.14.149","article-title":"Progress toward JAK1-selective inhibitors","volume":"7","author":"Menet","year":"2015","journal-title":"Future Med. Chem."},{"issue":"29","key":"10.1016\/j.bioorg.2024.107506_b0125","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.2174\/1568026622666220307124142","article-title":"Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs","volume":"29","author":"Zhao","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0130","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis","volume":"8","author":"Biggioggero","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.bioorg.2024.107506_b0135","doi-asserted-by":"crossref","unstructured":"A.B. Avci, E. Feist, G.R. Burmester, Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis, Rheumatology (Oxford, England) 60(Suppl 2) (2021) ii11-ii16.","DOI":"10.1093\/rheumatology\/keaa893"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107506_b0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107506_b0150","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3390\/cancers11111701","article-title":"Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1","volume":"11","author":"Liau","year":"2019","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.bioorg.2024.107506_b0155","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1021\/acs.jmedchem.3c00926","article-title":"Progress on the Pharmacological Targeting of Janus Pseudokinases","volume":"66","author":"Henry","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0160","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1042\/BST20130005","article-title":"New insights into the structure and function of the pseudokinase domain in JAK2","volume":"41","author":"Silvennoinen","year":"2013","journal-title":"Biochem. Soc. Trans."},{"issue":"Supplement_2","key":"10.1016\/j.bioorg.2024.107506_b0165","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1093\/ecco-jcc\/jjz206","article-title":"Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors","volume":"14","author":"Garrido-Trigo","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"6589","key":"10.1016\/j.bioorg.2024.107506_b0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107506_b0175","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2024.107506_b0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2004.00203.x","article-title":"Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways","volume":"202","author":"Kovanen","year":"2004","journal-title":"Immunol. Rev."},{"issue":"1\u20134","key":"10.1016\/j.bioorg.2024.107506_b0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10799899909036638","article-title":"The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus","volume":"19","author":"Heim","year":"1999","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0190","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/onc.2015.150","article-title":"Targeting JAK kinase in solid tumors: emerging opportunities and challenges","volume":"35","author":"Buchert","year":"2016","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107506_b0195","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00130832-200212000-00004","article-title":"Cytokines and their role in lymphoid development, differentiation and homeostasis","volume":"2","author":"Hofmann","year":"2002","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2024.107506_b0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107506_b0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.12164","article-title":"Therapeutic Targeting of the JAK\/STAT Pathway","volume":"114","author":"Aittomaki","year":"2014","journal-title":"Basic Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0210","doi-asserted-by":"crossref","first-page":"dev167643","DOI":"10.1242\/dev.167643","article-title":"JAK\/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates","volume":"146","author":"Herrera","year":"2019","journal-title":"Development"},{"key":"10.1016\/j.bioorg.2024.107506_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107506_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cells8080898","article-title":"Pathogenic and Therapeutic Relevance of JAK\/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent","volume":"8","author":"Alunno","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02981951","article-title":"Role of Jak kinases and STATs in cytokine signal transduction","volume":"73","author":"Leonard","year":"2001","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","article-title":"Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation","volume":"82","author":"Wen","year":"1995","journal-title":"Cell"},{"issue":"45","key":"10.1016\/j.bioorg.2024.107506_b0240","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107506_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4161\/jkst.19418","article-title":"Comparative evolutionary genomics of the STAT family of transcription factors","volume":"1","author":"Wang","year":"2012","journal-title":"Jak-Stat"},{"key":"10.1016\/j.bioorg.2024.107506_b0250","first-page":"i27","volume":"58","author":"Westhovens","year":"2019","journal-title":"Clinical Efficacy of New JAK Inhibitors under Development. Just More of the Same?, Rheumatology"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0255","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107506_b0260","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0265","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL (R)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J. Vet. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107506_b0270","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107506_b0275","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107506_b0280","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107506_b0285","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0290","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0295","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"20","key":"10.1016\/j.bioorg.2024.107506_b0300","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107506_b0305","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1080\/08820139.2021.1994589","article-title":"CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6\/JAK1\/STAT3 Signaling in Rheumatoid Arthritis","volume":"51","author":"Srivastava","year":"2022","journal-title":"Immunol. Invest."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0310","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.bioorg.2024.107506_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106211","article-title":"Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib","volume":"175","author":"Zhuang","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2024.107506_b0320","unstructured":"P. Smith, J. Wenzel, Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp), WO2021076124A1, 2021."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0325","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Brit. J. Dermatol."},{"issue":"D1","key":"10.1016\/j.bioorg.2024.107506_b0330","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107506_b0335","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#","article-title":"Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery","volume":"89","author":"Maurer","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2022.103781","article-title":"Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: A literature review on synthetic approaches, structure activity relationship, structural and target-based mechanisms","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0345","unstructured":"N.M.P. Administration, Pharmacopoeia of the people's Republic of China, https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypbzhgg\/20231012171156191.html (2020)."},{"key":"10.1016\/j.bioorg.2024.107506_b0350","year":"2006","journal-title":"Cheminformatics"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0355","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm300438j","article-title":"Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors","volume":"55","author":"Kulagowski","year":"2012","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107506_b0360","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bmcl.2016.02.035","article-title":"Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors","volume":"26","author":"Simov","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107506_b0365","article-title":"Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases","author":"Wrobleski","year":"2015","journal-title":"US8921368"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107506_b0370","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin","volume":"60","author":"Jones","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0375","article-title":"Cyanomethylpyrazole carboxamides as janus kinase inhibitors","author":"Brubaker","year":"2016","journal-title":"US9328099"},{"key":"10.1016\/j.bioorg.2024.107506_b0380","article-title":"Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors","author":"Brubaker","year":"2015","journal-title":"US8962608"},{"issue":"23","key":"10.1016\/j.bioorg.2024.107506_b0385","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1021\/acs.jmedchem.7b01135","article-title":"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties","volume":"60","author":"Siu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0390","doi-asserted-by":"crossref","unstructured":"PDB DOI: https:\/\/doi.org\/10.2210\/pdb6rsd\/pdb.","DOI":"10.2210\/pdb6rsd\/pdb"},{"issue":"20","key":"10.1016\/j.bioorg.2024.107506_b0395","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1111\/febs.16124","article-title":"A guide to the Michaelis-Menten equation: steady state and beyond","volume":"289","author":"Srinivasan","year":"2022","journal-title":"Febs J."},{"issue":"47","key":"10.1016\/j.bioorg.2024.107506_b0400","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1813988115","article-title":"Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists","volume":"115","author":"Liu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. u. s. a."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107506_b0405","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/cbdd.14024","article-title":"Designing of kinase hinge binders: A medicinal chemistry perspective","volume":"100","author":"Sharma","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2024.107506_b0410","doi-asserted-by":"crossref","unstructured":"A. Vulpetti, R. Bosotti, Sequence and structural analysis of kinase ATP pocket residues, Farmaco (Societa chimica italiana : 1989) 59(10) (2004) 759-65.","DOI":"10.1016\/j.farmac.2004.05.010"},{"key":"10.1016\/j.bioorg.2024.107506_b0415","series-title":"Next Generation Kinase Inhibitors: Moving beyond the ATP Binding\/catalytic Sites","first-page":"13","article-title":"Overview of Current Type I\/II Kinase Inhibitors","author":"Zhao","year":"2020"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0420","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/bioinformatics\/btg192","article-title":"ClustalW-MPI: ClustalW analysis using distributed and parallel computing","volume":"19","author":"Li","year":"2003","journal-title":"J. Bioinformatics"},{"issue":"W1","key":"10.1016\/j.bioorg.2024.107506_b0425","doi-asserted-by":"crossref","first-page":"W320","DOI":"10.1093\/nar\/gku316","article-title":"Deciphering key features in protein structures with the new ENDscript server","volume":"42","author":"Robert","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107506_b0430","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1021\/jm4004895","article-title":"Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2","volume":"56","author":"Zak","year":"2013","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2024.107506_b0435","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.1016\/j.bmcl.2012.10.008","article-title":"Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2","volume":"22","author":"Labadie","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0440","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0445","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cbdd.13667","article-title":"Comparative QSAR model generation using pyrazole derivatives for screening Janus kinase-1 inhibitors","volume":"95","author":"Sarithamol","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0450","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cell.2020.07.001","article-title":"An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells","volume":"182","author":"Vinogradova","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107506_b0455","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","article-title":"Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine","volume":"18","author":"Kavanagh","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0460","first-page":"539","article-title":"Strategy of molecular drug design: activity and druggability","volume":"45","author":"Guo","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"22","key":"10.1016\/j.bioorg.2024.107506_b0465","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107506_b0470","unstructured":"E.M. Agency, Filgotinib (Jyseleca\u00ae): summary of product characteristics, https:\/\/www.ema.europa.eu\/ (2020)."},{"key":"10.1016\/j.bioorg.2024.107506_b0475","unstructured":"K.J. Coffman, J.M. Duerr, N. Kaila, M.D. Parikh, M.R. Reese, T. Samad, S. SCIABOLA, J.B. Tuttle, M.L. Vazquez, P.R. Verhoest, Pyrrolo [2, 3-d] pyrimidine derivatives useful for inhibiting janus kinase, WO2016024185, 2016."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107506_b0480","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheumatol."},{"issue":"20","key":"10.1016\/j.bioorg.2024.107506_b0485","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107506_b0490","first-page":"4816970","article-title":"Computer-Aided Classification of New Psychoactive Substances","volume":"2021","author":"B\u0103rbulescu","year":"2021","journal-title":"J. Chem."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2024.107506_b0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Delivery Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107506_b0500","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioorg.2024.107506_b0505","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107506_b0510","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1432-1327.1999.00719.x","article-title":"Different protein turnover of interleukin-6-type cytokine signalling components","volume":"265","author":"Siewert","year":"1999","journal-title":"Eur. J. Biochem."},{"issue":"45","key":"10.1016\/j.bioorg.2024.107506_b0515","doi-asserted-by":"crossref","first-page":"23013","DOI":"10.1039\/D0NR05551D","article-title":"A biopolymer-based and inflammation-responsive nanodrug for rheumatoid arthritis treatment via inhibiting JAK-STAT and JNK signalling pathways","volume":"12","author":"Wang","year":"2020","journal-title":"Nanoscale"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107506_b0520","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"7414","key":"10.1016\/j.bioorg.2024.107506_b0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK\u2013STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107506_b0530","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tips.2022.04.006","article-title":"Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules","volume":"43","author":"Goebel","year":"2022","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824004115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824004115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:18:09Z","timestamp":1718414289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824004115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":106,"alternative-id":["S0045206824004115"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107506","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107506"}}